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Abstract: Background: Cluster headache cannot be cured, and not all attacks can be aborted or pre-
vented. Nevertheless, therapeutic guidelines focus solely on the attacks and ignore reverberations of
the disorder on patients’ lives. However, it is likely that not only pain reduces patients’ quality of life
(QoL). Objective: To investigate whether the interictal burden independently influence the QoL of sub-
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the EURO-HIS QoL scale. We built a generalised linear model and included the QoL as the dependent
variable. Independent variables comprised both the ictal and the interictal burden. Results: The data of
625 participants entered the analysis. Several aspects of the interictal burden independently reduced the
QoL. Among them were fear of pain, self-concealment, and private life difficulties due to the disorder.
Conclusion: Both the ictal and the interictal burden of cluster headache independently reduce patients’
QoL. We advocate adopting a more holistic approach to cluster headache management extending the focus
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Abstract
Background: Cluster headache cannot be cured, and not all attacks can be aborted or prevented. Nevertheless,
therapeutic guidelines focus solely on the attacks and ignore reverberations of the disorder on patients’ lives. However, it
is likely that not only pain reduces patients’ quality of life (QoL).
Objective: To investigate whether the interictal burden independently influence the QoL of subjects suffering from
cluster headache.
Methods: In this cross-sectional study, we asked patients with a self-reported cluster headache diagnosis to answer a
modified EUROLIGHT questionnaire that included the EURO-HIS QoL scale. We built a generalised linear model and
included the QoL as the dependent variable. Independent variables comprised both the ictal and the interictal burden.
Results: The data of 625 participants entered the analysis. Several aspects of the interictal burden independently reduced
the QoL. Among them were fear of pain, self-concealment, and private life difficulties due to the disorder.
Conclusion: Both the ictal and the interictal burden of cluster headache independently reduce patients’ QoL. We
advocate adopting a more holistic approach to cluster headache management extending the focus towards the afflicted
person and their QoL, which would generate novel therapeutic goals and strategies, complementary to treating and
preventing cluster headache attacks.
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Introduction
Excruciating pain is the most prominent symptom of clus-
ter headache (CH) attacks,1 but it is not the only way the
disorder inflicts suffering. For instance, in the interictal
period, many are frightened of future attacks, unable to
work, or disappointed by other’s lack of understanding.2
Nevertheless, therapeutic guidelines focus solely on abort-
ing and preventing headache spells.3–6
Attacks are a sine qua non of the disorder,7 and treating
them is crucial. However, acute medication does not abort,
and prophylaxis does not prevent every attack—CH can be
managed but not cured.8,9 So, it would be reasonable to
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endorse further therapeutic goals, to prioritise lightening its
impact on life. For instance, we might ask how we can help
patients thrive and obtain a desirable life position despite
the disorder.
Adopting a more holistic approach to health requires
study endpoints with a broader perspective. Quality of life
(QoL) may be a concept wide enough to meet this requisi-
tion and sufficiently clearly delineated for use in scientific
studies. The World Health Organization defines it as “an
individual’s perception of their position in life in the con-
text of the culture and value systems in which they live
and in relation to their goals, expectations, standards and
concerns.”10
Studies measuring CH patients’ QoL found it, generally,
poor.11–13 However, the development of therapeutic mea-
sures intended to increase the QoL requires a more differ-
entiated analysis of what lowers it. If we identified aspects
of the interictal burden that affect the QoL independently
from the attacks, we could attempt to tackle the disorder’s
impact on different fronts. However, it is currently
unknown if the interictal period has such weight or if the
ictal burden alone determines the QoL.
We refer to stresses and strains associated with the dis-
ease and present in the absence of a headache attack as
interictal burden.2
This study investigates whether potentially modifiable
aspects of the in-bout interictal burden—i.e. the interictal
burden present during the in-bout period—independently
influence the QoL of CH patients.
Methods
This study is a secondary analysis of data collected for the
EUROLIGHT CH project. We discussed the data collection
method and the study design in a previous paper.14 In brief,
from May to August 2012, we asked people with a self-
reported CH diagnosis to complete anonymously and
online a modified version of the EUROLIGHT question-
naire, which has been published elsewhere.14 Then, we
validated the diagnosis based on the reported symptoms.
Only data of patients whose symptoms met the criteria for
episodic or chronic CH according to the diagnostic criteria
published in the International Classification of Headache
Disorders, version 3 beta15 were taken for further analysis.
The inclusion criteria were participation consent and
CH diagnosis. We excluded participants whose diagnosis
could not be validated and patients with episodic CH out-
side the active phase of their headache disorder (“out-
bout”). Hence, only the data of patients with a chronic
CH or an episodic CH in the active phase (“in bout”)
entered further analysis. We decided to focus on patients
in the active period, because quality of life strongly
increases during the out-bout period.11 Besides, we
excluded patients if they had not answered all items
required for the analysis detailed below.
The available data determined the sample size. The
National Ethics Committee (CNER) Luxembourg
approved the study (CNER N 201206/13).
Modelling QoL
We measured QoL with the EURO-HIS QoL scale16 that
consists of eight items to which participants state the extent
of accordance on five-point Likert scales. Summating the
scores of the individual items yields the total score. The
lowest possible total score of the EURO-HIS QoL is eight,
and the highest is 40, with higher values indicating a better
QoL.16 Previously published standard values17 allowed the
transformation of the total scores into percentiles.
To answer the research question, we built a generalised
linear model and included the total score of the EURO-
HIS QoL as an ordinal-scaled dependent variable together
with the independent variables listed in Table 1. Given
that age and sex influence the EUOR-HIS QoL score,17
we entered these variables likewise into the model.
Furthermore, we included attack frequency and the CH-
type (episodic vs chronic) as covariate and cofactor,
respectively, into the model.






odds ratio 95% CI
“Do you avoid telling people that you have headaches?” 329/625 (52.6%) 0.018 0.703 0.525 to 0.942
“Do you feel that your family and friends understand and accept your
headaches?”
482/625 (77.7%) <0.001 2.490 1.756 to 3.530
“On the last day when you did not have a headache, were you anxious or
worried about your next headache episode?”
429/625 (68.6%) 0.002 0.600 0.434 to 0.831
“On the last day when you did not have a headache, was there anything
you could not do or did not do because you wanted to avoid getting a
headache?”
332/625 (53.1%) 0.014 0.679 0.499 to 0.924
“During the last three months, have your headaches caused difficulties in
your love life?”
396/625 (63.4%) <0.001 0.416 0.306 to 0.567
The answer “no” is the reference value. An odds ratio >1 suggests that the answer “yes” is associated with an increase in quality of life, whereas a ratio
<1 suggests that it is associated with a decrease. CI, confidence interval.
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The Test of Parallel Lines investigated whether the pro-
portional odds assumption held; Pearson’s chi-square sta-
tistic assessed the goodness of fit. Pseudo R-squared
Nagelkerke indicated the proportion of the variability of
the dependent variable explained by the independent
variables.
Odds ratios (OR), including their 95% confidence inter-
val (CI), indicate the influence of individual variables on
the QoL. In dichotomous variables, we chose the answer
“no” as the reference category. So, an OR > 1 implies that
participants who answered “yes” to the variable in question
have greater odds of having a higher QoL than patients who
answered “no”. Conversely, an OR < 1 implies that parti-
cipants who answered “yes” have smaller odds of having a
higher QoL than patients who answered “no”.
Further statistical analyses
We report interval scaled variables as means and standard
deviations and categorical variables as frequencies. The
statistical analysis was performed at the university hospital
of Zurich using IBM SPSS version 25 (IBM, USA). The
significance level was 0.05.
Data availability statement
The data collected and analysed for this study are available
from the corresponding author on reasonable request.
Results
Seven hundred seventy-four participants met the inclusion
criteria, of whom 625 had responded to all variables
included in the regression model and entered further anal-
ysis. Their mean age was 42+ 10 years; 68.5% (428/625)
were male, and 32.6% (204/625) suffered from chronic CH.
Participants reached an average score of 27+ 6 points
(range: 9 to 40 points) on the EURO-HIS QoL scale. We
used standard values published by Brähler et al. to translate
the total scores into percentiles;17 72.2% of the participants
(451/625) had values below the median and 57% (356/625)
below the lower quartile. Only 12.2% (76/625) reached a
score above the upper quartile.
Table 1 summarises the parameter estimates of vari-
ables representing the interictal burden. Furthermore, age
(P ¼ 0.002), attack frequency (P ¼ 0.003), and CH-type
(P < 0.001) influenced the QoL statistically significantly,
while—despite a noticeable trend—sex (P ¼ 0.089) did
not. The estimated odds ratio of the variable “age” was
1.022 (95% CI 1.008 to 1.037), indicating that higher val-
ues are associated with an increased QoL. The variable
“attack frequency during the last 30 days” had an odds ratio
of 0.976 (95% CI 0.960 to 0.992), suggesting that a higher
attack frequency is associated with decreasing QoL.
Finally, the odds ratio of 0.497 (95% CI 0.361 to 0.684)
imply that compared with episodic CH, chronic CH is asso-
ciated with a significantly lower QoL.
The Test of Parallel Lines confirmed the proportional
odds assumption (P ¼ 0.243), and Pearson’s Chi-square
statistic indicated a good model fit (P > 0.999). Pseudo
R-squared Nagelkerke was 0.293.
Discussion
Generally, the QoL was poor in this sample of CH patients.
Various influencing factors in both the ictal and the inter-
ictal period had an independent negative impact. Families’
and friends’ lack of understanding and difficulties in the
love life weighed particularly heavily. Notably, not all
patients experienced every aspect of the interictal burden,
suggesting that none is an inevitable consequence of the
disorder.
Many could not avert the disease’s impact on their social
network and endured difficulties in their partnerships,
implying that CH does not affect them alone. Instead, it
seems that the disease makes it difficult for them to be in a
relationship with others and for others to be in a relation-
ship with them. Nevertheless, the momentous negative con-
sequences of others’ lacking acceptance highlight that CH
does not reduce the need for love and support.
Research in other disorders suggests that partners are a
great source of strength and support. However, they also
suffer together with their significant other and may feel
emotionally overwhelmed by the imposed disability, too.
Notably, psychological interventions may help couples
cope, increase the QoL, and reduce distress.18 Conse-
quently, when treating CH patients, it is worth considering
the importance of their partners as well.
CH is on patients’ minds—even in the absence of pain.
Concealing the disorder, trying to prevent, and worrying
about the next headache spell, all indicate fear.19,20 Patients
likely are frightened by the prospect of future attacks and
the envisioned reaction of their social circle to disclosing
their disorder.
Fear of pain is associated with anxiety and depression,
leads to avoidance and hypervigilance, and correlates
with self-reported disability.21–23 It is unknown whether
therapeutic interventions can reduce this type of fear in
patients with CH. However, cognitive-behavioural therapy
was effective in this regard in patients with other pain
disorders,24 suggesting that fear may likewise not be invari-
able among CH sufferers.
The tendency to hide from others information perceived
as distressing refers to the concept of “self-concealment”
that Larson and Chastain introduced in 1990.20 Self-
concealment is associated with anxiety and depression20 and
prevents patients from seeking help.25 However, Luoma
et al. reported that treating individuals with substance abuse
according to Acceptance and Commitment Therapy (ACT)
principles significantly reduces self-concealment.26
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Consequently, concealment is probably neither invariable
nor necessary in patients with CH, too.
Overall, our analysis confirms that the interictal burden
independently reduces the QoL, and—albeit yet to be
proved—therapeutic measures can likely alleviate the inter-
ictal burden and increase the QoL. Hence, though there is no
interictal burden without an ictal burden, focusing solely on
the latter implies missing an opportunity to relieve distress
because drugs cannot prevent or abort all attacks.8,9
Based on these findings, we advocate broadening the
therapeutic goals and attempting to maximise the QoL.
This approach embraces the idea of patient-centred care,
which holds that considering patients’ families in the per-
sonalised care plan may facilitate meeting the objective of
emotional—not just physical—well-being.27
Finally, putting the patient—instead of the disorder—in
the centre of therapeutic efforts seconds Sir William Osler’s
famous quote, “The good physician treats the disease; the
great physician treats the patient who has the disease.”28
Strengths and limitations
The large sample included in the analysis is a strength of
this study. We have already discussed limitations due to the
study design and the algorithm used to validate the diag-
nosis elsewhere.14 A further limitation is that the list of
interictal burdens analysed in this study is not exhaustive. It
is possible—and even likely given the Pseudo R-square of
0.293—that other, yet to be described types of burden, such
as access to health care29 and life-style related comorbid-
ities30 exert an additional influence on CH patients’ QoL.
Conclusion
Therapeutic goals need to accommodate the therapeutic
possibilities. When confronted with a disorder that, like
CH, cannot be cured, efforts should focus on controlling
symptoms. However, symptoms of CH are not just pain but
also difficulties to cope, difficulties in love life, and diffi-
culties that arise from others’ lack of understanding. We
advocate shifting the focus towards the afflicted person and
their QoL, because then, besides treating and preventing
the attacks, additional therapeutic goals and options
emerge.
Key findings
 The QoL is poor in patients with chronic CH or
episodic CH in the active period.
 Various factors in both the ictal and the interictal
period influence independently and negatively
the QoL.
 Given that not only the ictal burden but also the
interictal burden can potentially be modified, we
advocate focusing not solely on aborting and pre-
venting headache spells.
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